Login / Signup

Adjuvant camrelizumab plus apatinib in resected hepatocellular carcinoma with microvascular invasion: a multi-center real world study.

Jingzhong OuyangFeng YeYanzhao ZhouXu ChangZhengzheng WangQingjun LiYu TangJianqiang CaiJinxue ZhouZhen HuangHong Zhao
Published in: Hepatobiliary surgery and nutrition (2024)
Postoperative adjuvant camrelizumab plus apatinib significantly improved the RFS benefits with acceptable toxicities in patients with HCC with MVI.
Keyphrases
  • early stage
  • patients undergoing
  • lymph node